This page lists all known medications that could potentially lead to 'Abnormal Glabellar Reflex' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

Moderate to severe glabellar lines may be effectively and safely treated with YY001, a new recombinant botulinum toxin type A product.

Please provide your email address to receive an email when new articles are posted on . A split-face comparison found no difference between onabotulinumtoxinA and prabotulinumtoxinA for the treatment ...

Credit: Hugel. Letybo, an acetylcholine release inhibitor and a neuromuscular blocking agent, was approved in March 2024 based on data from three phase 3 trials. Letybo should be administered no more ...

The potency units of Letybo are not interchangeable with other preparations of botulinum toxin products. The Food and Drug Administration (FDA) has approved Letybo (letibotulinumtoxinA-wlbg) for the ...

Please provide your email address to receive an email when new articles are posted on . New phase 2 results showed 40 units of Jeuveau sustained improvements in glabellar lines up to 6 months. Adverse ...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel Aesthetics announces the publication of the BLESS III clinical trial in the Aesthetic Surgery Journal. The published data comes as Hugel is accelerating ...

–TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that Shanghai Fosun ...

–All primary and secondary endpoints were met for both Phase 3 studies (M21-500 and M21-508). –Results support BoNT/E as a novel botulinum neurotoxin serotype E characterized by a rapid onset of ...